Pentetreotide

DB12602ApprovedWithdrawnSmall molecule

Pentetreotide is a somatostatin receptor inhibitor, available in a kit with Indium-111, used as a contrast agent in the visualization of somatostatin receptor-positive neuroendocrine tumours. Pentetreotide has been used in trials studying the diagnosis of Cushing's syndrome.

Mechanism: Pharmacologically active on Somatostatin receptor type 5, Somatostatin receptor type 2, and Somatostatin receptor
Curator reviewed
Formula / weight: C₆₃H₈₇N₁₃O₁₉S₂ · 1394.58 g/mol (avg)
Code names: SDZ 215-811 · SDZ 215-811S

Resolves to

Compound

UNIIG083B71P98CAS138661-02-6PubChem72128

Clinical / RWD

RxNorm69893

Structure

InChIKeyCNLWNYCFDMAZCB-HUVROIHYSA-NSMILES

C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN(CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O)CC(O)=O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC2=CNC3=CC=CC=C23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1

Targets

P35346SSTR5P30874SSTR2

What you can answer from here — as of July 07, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4Structured indicationsCondition, population, route and combination as fields, not prose

3Marketed productsAcross 3 countries and 3 labellers

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pentetreotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account